RecruitingPsoriasis

Taltz in Combination With Enstilar for Psoriasis

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Enstilar in combination with Taltz for plaque psoriasis.

Sponsor: Psoriasis Treatment Center of Central New Jersey

✓ Male or female adult ≥ 18 years of age;
✓ Diagnosis of chronic plaque-type
✓ Body Surface Area between 3%-8%.
✓ Patient has been treated with Taltz for a minimum of 24 weeks
✓ Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options: hormonal contraception; intrauterine device (IUD); tubal ligation; or partner's vasectomy; Male or female condom diaphragm with spermicide, cervical cap with spermicide, or contraceptive sponge with spermicide.
✓ Subject must be in general good health (except for psoriasis) as judged by the Investigator, based on medical history, physical examination
✓ Able and willing to give written informed consent prior to performance of any study-related procedures.

✕ ˂3% or \>8% BSA
✕ Patient not receiving Taltz, or receiving Taltz \<24 weeks
✕ Any condition, which would place the subject at unacceptable risk if he/she were to participate in the study.
✕ Pregnant or breast feeding, or considering becoming pregnant during the study.
✕ Use of any investigational drug within 4 weeks prior to randomization, or within 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer).
✕ Use of oral systemic medications for the treatment of psoriasis within 4 weeks.
✕ Patient used other topical therapies to treat within 2 weeks of the Baseline Visit.
✕ Patient received UVB phototherapy within 2 weeks of Baseline.

East Windsor

Source: ClinicalTrials.gov · NCT04372277 · last updated 2020-05-04